Moleculex has created the world's first "intraoral" wound dressing to treat severe oral ulcers caused by cancer treatment. Oral mucositis is a major side effect of cancer therapy , which can cause extreme pain and may even force patients to stop treatment. Using our exclusive MuCover® mucoadhesive film technology, Moleculex has developed a large-area intraoral wound dressing that acts as a dedicated artificial skin in the mouth. This solution is set to become the standard of care for oral mucosal wounds and has been approved by the Taiwan FDA in 2023. 
The application of MuCover® mucoadhesive film is extremely simple that enables easy, precise and sustained drug delivery in challenging location, which can be used as a transmucosal delivery system for the development of 505(b)(2) new drugs. Featuring with degradable design, MuCover® is ideal to avoid risk of  adhesive-related injury to the mucosal tissue.

MoleculeX Co., Ltd.

Org chart

Teams

Offices